Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790171 | 0.85 | KDM4E (0.40) | KMT2ALMNAALDH1A1 | |
| Adamantane SCHEMBL3794380 | 0.83 | MEN1 (0.31) | MEN1KMT2AALDH1A1HTT | |
| SCHEMBL3794378 | 0.78 | KMT2A (0.40) | MEN1KMT2AP2RX7EPHX2LMNA | |
| SCHEMBL11991284 | 0.76 | LMNA (0.38) | MEN1KMT2AEPHX2LMNACA12 | |
| SCHEMBL3786558 | 0.74 | KMT2A (0.35) | MEN1KMT2ALMNACA12ALDH1A1 | |
| SCHEMBL242790 | 0.72 | P2RX7 (0.36) | MEN1KMT2AP2RX7EPHX2CA12 | |
| SCHEMBL515601 | 0.72 | P2RX7 (0.37) | MEN1KMT2AP2RX7EPHX2CA12 | |
| SCHEMBL19529502 | 0.71 | ALDH1A1 (0.42) | MEN1KMT2AP2RX7EPHX2LMNA | |
| SCHEMBL24861662 | 0.70 | ALDH1A1 (0.42) | MEN1KMT2AEPHX2LMNAALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL3420430 | 0.69 | P2RX7 (0.38) | MEN1KMT2AP2RX7EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283104-B2 | Sulfonate and its derivative, photosensitive acid generator, and resist composition and patterning process using the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20100209827-A1 | NOVEL SULFONATE AND ITS DERIVATIVE, PHOTOSENSITIVE ACID GENERATOR, AND RESIST COMPOSITION AND PATTERNING PROCESS USING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209827-A1 | NOVEL SULFONATE AND ITS DERIVATIVE, PHOTOSENSITIVE ACID GENERATOR, AND RESIST COMPOSITION AND PATTERNING PROCESS USING THE SAME | DAP3, MRPS23, ASIC3 | MEN1 4475/4885KMT2A 2736/4885P2RX7 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.